English

Juno Therapeutics, Inc.

EDGAR

JUNO Annual report (10-K) · filed 2018-03-01

15 filing records in this dataset, filed from 2014-11-17 to 2018-03-01. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

26.5 million USD

2017 Q4 · USD

Exact inputs and evidence

Revenue: 26460000 USD Source

Operating margin

-522.33%

2017 Q4 · %

Exact inputs and evidence

Operating Income: -138208000 USD Source
Revenue: 26460000 USD Source

Operating cash flow

-92.9 million USD

2017 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -225033000 USD Source
Operating Cash Flow: -132169000 USD Source

Free cash flow

-96.9 million USD

2017 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -225033000 USD Source
Operating Cash Flow: -132169000 USD Source
Capital Expenditure: 60924000 USD Source
Capital Expenditure: 56903000 USD Source

Cash and cash equivalents: 233 million USD 2017-12-31 Source
Exact value

232781000 USD
Long-term debt including current maturities: 10.8 million USD 2017-12-31 Source
Exact value

10839000 USD
Shares outstanding: 114 million shares 2017-12-31 Source
Exact value

114313000 shares

Reported share-count change

10.55% · 10.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

103403000 shares · 2016-12-31· Source
114313000 shares · 2017-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

112 million USD

2017-01-01 – 2017-12-31

Exact inputs and evidence

Revenue: 19327000 USD · 2017-01-01 – 2017-03-31 Source
Revenue: 21268000 USD · 2017-04-01 – 2017-06-30 Source
Revenue: 44816000 USD · 2017-07-01 – 2017-09-30 Source
Revenue: 26460000 USD · 2017-10-01 – 2017-12-31 Source

Net income

-437 million USD

2017-01-01 – 2017-12-31

Exact inputs and evidence

Net income: -82197000 USD · 2017-01-01 – 2017-03-31 Source
Net income: -100740000 USD · 2017-04-01 – 2017-06-30 Source
Net income: -118133000 USD · 2017-07-01 – 2017-09-30 Source
Net income: -136036000 USD · 2017-10-01 – 2017-12-31 Source

Operating cash flow

-225 million USD

2017-01-01 – 2017-12-31

Exact inputs and evidence

Operating cash flow: -53928000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -91894000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -53928000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -132169000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -91894000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -225033000 USD · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -132169000 USD · 2017-01-01 – 2017-09-30 Source

Capital expenditure

60.9 million USD

2017-01-01 – 2017-12-31

Exact inputs and evidence

Capital expenditure: 21152000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 42991000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 21152000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 56903000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 42991000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 60924000 USD · 2017-01-01 – 2017-12-31 Source
Capital expenditure: 56903000 USD · 2017-01-01 – 2017-09-30 Source

Free cash flow

-286 million USD

2017-01-01 – 2017-12-31

Exact inputs and evidence

Operating cash flow: -53928000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -91894000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -53928000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -132169000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -91894000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -225033000 USD · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -132169000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 21152000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 42991000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 21152000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 56903000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 42991000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 60924000 USD · 2017-01-01 – 2017-12-31 Source
Capital expenditure: 56903000 USD · 2017-01-01 – 2017-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2018-03-01.

Financial data available through: 2017-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2017-12-31
Operating income: 4 of 11 periods available· newest 2017-12-31
Net income: 4 of 11 periods available· newest 2017-12-31
Operating cash flow: 4 of 11 periods available· newest 2017-12-31
Capital expenditure: 4 of 11 periods available· newest 2017-12-31
Total assets: 4 of 11 periods available· newest 2017-12-31
liabilities: No compatible figures in this window
Current assets: 4 of 11 periods available· newest 2017-12-31
Current liabilities: 4 of 11 periods available· newest 2017-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2017-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2017-12-31
Shares outstanding: 4 of 11 periods available· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+41%

Prior period

USD 79.36 million

2016-01-01 – 2016-12-31
Current period

USD 111.87 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

111871000 − 79356000 = 32515000 USD

79356000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
111871000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Year-over-year change in Revenue: 32515000 USD Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 111871000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#524786 Filing: 000159486418000005 Input fundies:Revenue: 79356000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#523791 Filing: 000159486418000005
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 191.53 million

Prior period

−USD 245.58 million

2016-01-01 – 2016-12-31
Current period

−USD 437.11 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-437106000 − -245580000 = -191526000 USD

-245580000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-437106000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Year-over-year change in Net income: -191526000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -437106000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#489058 Filing: 000159486418000005 Input fundies:NetIncome: -245580000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#488060 Filing: 000159486418000005
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 35.22 million

Prior period

−USD 189.81 million

2016-01-01 – 2016-12-31
Current period

−USD 225.03 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-225033000 − -189809000 = -35224000 USD

-189809000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-225033000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Year-over-year change in Operating cash flow: -35224000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -225033000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486852 Filing: 000159486418000005 Input fundies:OperatingCashFlow: -189809000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486639 Filing: 000159486418000005
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+8.3%

Prior period

USD 56.25 million

2016-01-01 – 2016-12-31
Current period

USD 60.92 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

60924000 − 56246000 = 4678000 USD

56246000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
60924000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Year-over-year change in Capital expenditure: 4678000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 60924000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508800 Filing: 000159486418000005 Input fundies:CapitalExpenditure: 56246000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508589 Filing: 000159486418000005
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 111.87 million 100% of revenue
Operating costs Derived USD 559.65 million 500% of revenue
Operating income −USD 447.77 million −400% of revenue
Tax, interest and other Derived −USD 10.67 million −9.5% of revenue
Net income −USD 437.11 million −391% of revenue

Cash

Operating cash flow −USD 225.03 million −201% of revenue
Capital expenditure USD 60.92 million 54% of revenue
Free cash flow Derived −USD 285.96 million −256% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Not shown: operating income or net income is not reported.
2015 Operating loss: operating costs were 1,440% of revenue.
2016 Operating loss: operating costs were 422% of revenue.
2017 Operating loss: operating costs were 500% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	0	232758000 Derived	-232758000	10649000 Derived	-243407000	-85503000 Derived	Source 2014-01-01 – 2014-12-31: 0 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -232758000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -243407000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -82545000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 2958000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	18215000	262315000 Derived	-244100000	-4724000 Derived	-239376000	-20859000 Derived	Source 2015-01-01 – 2015-12-31: 18215000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -244100000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -239376000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 7325000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 28184000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	79356000	334960000 Derived	-255604000	-10024000 Derived	-245580000	-246055000 Derived	Source 2016-01-01 – 2016-12-31: 79356000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -255604000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -245580000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -189809000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 56246000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	111871000	559645000 Derived	-447774000	-10668000 Derived	-437106000	-285957000 Derived	Source 2017-01-01 – 2017-12-31: 111871000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -447774000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -437106000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -225033000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 60924000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 111.9M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	0	Revenue: 0 Open source
20152015-12-31	Revenue	18215000	Revenue: 18215000 Open source
20162016-12-31	Revenue	79356000	Revenue: 79356000 Open source
20172017-12-31	Revenue	111871000	Revenue: 111871000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

41% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20152015-12-31	Year over year	No prior comparable period	Revenue: 18215000 Open source Revenue: 0 Open source
20162016-12-31	Year over year	335.7%	Revenue: 79356000 Open source Revenue: 18215000 Open source
20172017-12-31	Year over year	41%	Revenue: 111871000 Open source Revenue: 79356000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -400.3% 2017

Net margin -390.7% 2017

Free cash flow margin -255.6% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	Not reported	Operating Income: -232758000 Open source Revenue: 0 Open source
20152015-12-31	Operating margin	-1,340.1%	Operating Income: -244100000 Open source Revenue: 18215000 Open source
20162016-12-31	Operating margin	-322.1%	Operating Income: -255604000 Open source Revenue: 79356000 Open source
20172017-12-31	Operating margin	-400.3%	Operating Income: -447774000 Open source Revenue: 111871000 Open source
20142014-12-31	Net margin	Not reported	Net Income: -243407000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	-1,314.2%	Net Income: -239376000 Open source Revenue: 18215000 Open source
20162016-12-31	Net margin	-309.5%	Net Income: -245580000 Open source Revenue: 79356000 Open source
20172017-12-31	Net margin	-390.7%	Net Income: -437106000 Open source Revenue: 111871000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -82545000 Open source Capital Expenditure: 2958000 Open source
20152015-12-31	Free cash flow margin	-114.5%	Revenue: 18215000 Open source Operating Cash Flow: 7325000 Open source Capital Expenditure: 28184000 Open source
20162016-12-31	Free cash flow margin	-310.1%	Revenue: 79356000 Open source Operating Cash Flow: -189809000 Open source Capital Expenditure: 56246000 Open source
20172017-12-31	Free cash flow margin	-255.6%	Revenue: 111871000 Open source Operating Cash Flow: -225033000 Open source Capital Expenditure: 60924000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -225M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	-82545000	Operating Cash Flow: -82545000 Open source
20152015-12-31	Operating cash flow	7325000	Operating Cash Flow: 7325000 Open source
20162016-12-31	Operating cash flow	-189809000	Operating Cash Flow: -189809000 Open source
20172017-12-31	Operating cash flow	-225033000	Operating Cash Flow: -225033000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -286M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-85503000	Operating Cash Flow: -82545000 Open source Capital Expenditure: 2958000 Open source
20152015-12-31	Free cash flow	-20859000	Operating Cash Flow: 7325000 Open source Capital Expenditure: 28184000 Open source
20162016-12-31	Free cash flow	-246055000	Operating Cash Flow: -189809000 Open source Capital Expenditure: 56246000 Open source
20172017-12-31	Free cash flow	-285957000	Operating Cash Flow: -225033000 Open source Capital Expenditure: 60924000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Liabilities / assets	Not reported	Total Assets: 489163000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 1445128000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 1349464000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 1434836000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.61× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	4.37×	Current Assets: 439235000 Open source Current Liabilities: 100593000 Open source
20152015-12-31	Current assets / current liabilities	7.95×	Current Assets: 951839000 Open source Current Liabilities: 119728000 Open source
20162016-12-31	Current assets / current liabilities	6.72×	Current Assets: 772332000 Open source Current Liabilities: 114892000 Open source
20172017-12-31	Current assets / current liabilities	3.61×	Current Assets: 753354000 Open source Current Liabilities: 208752000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 243.41 million Exact value Exact value: -243407000 USD 2014-01-01 – 2014-12-31: -243407000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Juno Therapeutics, Inc. · 2014-12-31 Juno Therapeutics, Inc. (edgar:1594864) Net Income: -243407000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -243407000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486417000009/juno-20161231.xml#505295 Filing: 000159486417000009 The citation records this snapshot. The page link may show a newer release later.	−USD 82.55 million Exact value Exact value: -82545000 USD 2014-01-01 – 2014-12-31: -82545000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Juno Therapeutics, Inc. · 2014-12-31 Juno Therapeutics, Inc. (edgar:1594864) Operating Cash Flow: -82545000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -82545000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486417000009/juno-20161231.xml#504660 Filing: 000159486417000009 The citation records this snapshot. The page link may show a newer release later.	USD 2.96 million Exact value Exact value: 2958000 USD 2014-01-01 – 2014-12-31: 2958000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Juno Therapeutics, Inc. · 2014-12-31 Juno Therapeutics, Inc. (edgar:1594864) Capital Expenditure: 2958000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2958000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486417000009/juno-20161231.xml#527074 Filing: 000159486417000009 The citation records this snapshot. The page link may show a newer release later.	−USD 85.5 million Calculation and evidence -82545000 − 2958000 USD Exact free cash flow: -85503000 USD 2014-01-01 – 2014-12-31: -82545000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 2958000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Juno Therapeutics, Inc. · 2014-12-31 Juno Therapeutics, Inc. (edgar:1594864) Free cash flow: -85503000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -82545000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486417000009/juno-20161231.xml#504660 Filing: 000159486417000009 Input fundies:CapitalExpenditure: 2958000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486417000009/juno-20161231.xml#527074 Filing: 000159486417000009 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 239.38 million Exact value Exact value: -239376000 USD 2015-01-01 – 2015-12-31: -239376000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Juno Therapeutics, Inc. · 2015-12-31 Juno Therapeutics, Inc. (edgar:1594864) Net Income: -239376000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -239376000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#487065 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	USD 7.33 million Exact value Exact value: 7325000 USD 2015-01-01 – 2015-12-31: 7325000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Juno Therapeutics, Inc. · 2015-12-31 Juno Therapeutics, Inc. (edgar:1594864) Operating Cash Flow: 7325000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 7325000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486429 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	USD 28.18 million Exact value Exact value: 28184000 USD 2015-01-01 – 2015-12-31: 28184000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Juno Therapeutics, Inc. · 2015-12-31 Juno Therapeutics, Inc. (edgar:1594864) Capital Expenditure: 28184000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 28184000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508378 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	−USD 20.86 million Calculation and evidence 7325000 − 28184000 USD Exact free cash flow: -20859000 USD 2015-01-01 – 2015-12-31: 7325000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 28184000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Juno Therapeutics, Inc. · 2015-12-31 Juno Therapeutics, Inc. (edgar:1594864) Free cash flow: -20859000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 7325000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486429 Filing: 000159486418000005 Input fundies:CapitalExpenditure: 28184000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508378 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 245.58 million Exact value Exact value: -245580000 USD 2016-01-01 – 2016-12-31: -245580000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Juno Therapeutics, Inc. · 2016-12-31 Juno Therapeutics, Inc. (edgar:1594864) Net Income: -245580000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -245580000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#488060 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	−USD 189.81 million Exact value Exact value: -189809000 USD 2016-01-01 – 2016-12-31: -189809000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Juno Therapeutics, Inc. · 2016-12-31 Juno Therapeutics, Inc. (edgar:1594864) Operating Cash Flow: -189809000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -189809000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486639 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	USD 56.25 million Exact value Exact value: 56246000 USD 2016-01-01 – 2016-12-31: 56246000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Juno Therapeutics, Inc. · 2016-12-31 Juno Therapeutics, Inc. (edgar:1594864) Capital Expenditure: 56246000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 56246000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508589 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	−USD 246.06 million Calculation and evidence -189809000 − 56246000 USD Exact free cash flow: -246055000 USD 2016-01-01 – 2016-12-31: -189809000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 56246000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Juno Therapeutics, Inc. · 2016-12-31 Juno Therapeutics, Inc. (edgar:1594864) Free cash flow: -246055000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -189809000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486639 Filing: 000159486418000005 Input fundies:CapitalExpenditure: 56246000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508589 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 437.11 million Exact value Exact value: -437106000 USD 2017-01-01 – 2017-12-31: -437106000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Net Income: -437106000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -437106000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#489058 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	−USD 225.03 million Exact value Exact value: -225033000 USD 2017-01-01 – 2017-12-31: -225033000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Operating Cash Flow: -225033000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -225033000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486852 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	USD 60.92 million Exact value Exact value: 60924000 USD 2017-01-01 – 2017-12-31: 60924000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Capital Expenditure: 60924000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 60924000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508800 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.	−USD 285.96 million Calculation and evidence -225033000 − 60924000 USD Exact free cash flow: -285957000 USD 2017-01-01 – 2017-12-31: -225033000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 60924000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Juno Therapeutics, Inc. · 2017-12-31 Juno Therapeutics, Inc. (edgar:1594864) Free cash flow: -285957000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:01:43Z Snapshot: 5827ed1281becf68a368c6e8a0f068c6d5bf9650ce9c117610c10d280aefd059 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1594864?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -225033000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#486852 Filing: 000159486418000005 Input fundies:CapitalExpenditure: 60924000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1594864/000159486418000005/juno-20171231.xml#508800 Filing: 000159486418000005 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

15 filings · 902 latest values · 902 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001594864, 1594864, JUNO, edgar:1594864

Also known as Juno Therapeutics, Inc.

Juno Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation